NASD · Healthcare · Biotechnology · USA
Zevra Therapeutics Inc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Zevra Therapeutics is a commercial-stage pharmaceutical company developing therapies for rare diseases. The company markets MIPLYFFA for Niemann-Pick disease type C and OLPRUVA for urea cycle disorders in the United States, and is advancing celiprolol in clinical trials for Vascular Ehlers-Danlos syndrome. Zevra also receives royalties from AZSTARYS for attention deficit and hyperactivity disorder through a partnership arrangement.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Zevra Therapeutics Inc stock.
Overvalued: intrinsic value $5.45 per share, market price $10.16, margin of safety -86.3% (as of 2026-10-19).
A 2.4x revenue multiple, discounted for its losses, values the shares at $5.45; the price of $10.16 is 86% above that value.
Leak Score: 35/100 on 12 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
54 more in this industry show a wider margin of safety.
ZVRA is overvalued (as of the 2026-10-19 close). A 2.4x revenue multiple, discounted for its losses, values the shares at $5.45; the price of $10.16 is 86% above that value.
$5.45 per share (as of the 2026-10-19 close), against a market price of $10.16. That is a margin of safety of -86.3%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
35 out of 100, which we rate "On Watch", on 12 of 12 value investing signals.